Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Stomach Neoplasms 17Nasopharyngeal Carcinoma 15Triple Negative Breast Neoplasms 13Esophageal Squamous Cell Carcinoma 13Breast Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Melanoma 6Recurrence 5Neoplasm Metastasis 5Lung Neoplasms 5Hodgkin Disease 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Osteosarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Liver Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Solid Tumor 2Rectal Neoplasms 2NSCLC 2

Interventions

Doxorubicin 6Trabectedin 5pazopanib 4Radiotherapy 4ribociclib 3pembrolizumab 3palbociclib 3Gemcitabine 3brostallicin 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Immunoglobulin G 2Imatinib Mesylate 2Ifosfamide 2Docetaxel 2Dexamethasone 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1tanespimycin 1talimogene laherparepvec 1sotigalimab 1soblidotin 1sitravatinib 1saracatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liposarcoma × camrelizumab × Clear all
NCT06694324 2024-11-19

First-line Treatment of Advanced/unresectable DDLPS

Fudan University

Phase 2 Not yet recruiting
49 enrolled
Sarcoma

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡